Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.


Date Title Topic
15 Sep 2015 First Regulatory Approval of Cobimetinib in Switzerland Melanoma - Anticancer agents & Biologic therapy
14 Sep 2015 New American Cancer Society Guidelines Address Long-Term Needs of Colorectal Cancer Survivors Gastrointestinal cancers
14 Sep 2015 Study Defines Criteria for MET-driven Lung Cancer Suitable for Crizotinib Treatment Translational research - Lung and other thoracic tumours
07 Sep 2015 FDA Approves Rolapitant for Nausea and Vomiting From Chemotherapy Palliative and supportive care
01 Sep 2015 eHealth Application to Improve Care for Cancer Patients Palliative and supportive care
27 Aug 2015 ESMO Press Release: ESMO Launches Women for Oncology Award
26 Aug 2015 FDA Extends Use of Eltrombopag in Young Children With ITP Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
24 Aug 2015 ESMO Press Release: ESMO Honours Exceptional Oncologists
20 Aug 2015 FDA Approves a Laboratory Immunohistochemical Test That Identifies Whether the ALK Protein is Present in a NSCLC Tissue Sample Pathology/Molecular biology - Lung and other thoracic tumours
18 Aug 2015 Melanoma in Adolescent and Young Adult Patients With Cancer Cancer in Special Situations - Melanoma
10 Aug 2015 A Survey on Current RAS Mutation Testing Practices in Europe Pathology/Molecular biology - Gastrointestinal cancers
03 Aug 2015 NICE Issues Guideline on Melanoma to Reduce Variation in Care Melanoma - Immuno-oncology - Anticancer agents & Biologic therapy
30 Jul 2015 EMA Recommends Granting a Marketing Authorisation for Pemetrexed Lilly and Pemetrexed Sandoz Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 Jul 2015 FDA Approves New Treatment for Most Common Form of Advanced Skin Cancer Anticancer agents & Biologic therapy
28 Jul 2015 EMA Recommends a Change to the Terms of the Marketing Authorisation for Dabrafenib Melanoma - Anticancer agents & Biologic therapy